Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m - PMLiVE The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology

#EliLilly #Camurus #cardiometabolichealth #incretinproducts #FluidCrystal #dualGIPandGLP1receptoragonists #tripleGIP #glucagonreceptoragonists #GLP1receptoragonists #amylinreceptoragonists #obesity #diabetes #RNAitherapeutics #OliXPharmaceuticals #MASH
pmlive.com/pharma_news/...